Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lopinavir/ritonavir once-daily versus twice-daily in treatment-experienced HIV-1 infection
2006-000748-14Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lopinavir + ritonavir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Proportion of subjects responding at Week 48. Started Jun 2006; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2006-000748-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000748-14.